## GUIDELINE INTERPRETATION

**1375**  
Influence of SCENIC recommendations on terminology used for histopathologic diagnosis of inflammatory bowel disease-associated dysplasia  
Li Y, Wang HL

## REVIEW

**1388**  
*KAI1/CD82* gene and autotaxin-lysophosphatidic acid axis in gastrointestinal cancers  
Wang S, Chen J, Guo XZ

**1406**  
Poorly cohesive cells gastric carcinoma including signet-ring cell cancer: Updated review of definition, classification and therapeutic management  
Drubay Y, Nuyens F, Renaud F, Adenis A, Eveno C, Piessen G

**1429**  
Lymph node regression grading of locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy  
He L, Xiao J, Zheng P, Zhong L, Peng Q

## MINIREVIEWS

**1446**  
Immunotherapy in biliary tract cancers: Current evidence and future perspectives  
Uson Junior PLS, Araujo RL

**1456**  
Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression  
Zhang CY, Liu S, Yang M

**1469**  
Angiogenesis in gastrointestinal stromal tumors: From bench to bedside  
Papadakos SP, Tsagkaris C, Papadakis M, Papazoglou AS, Moysidis DV, Zografos CG, Theocharis S

**1478**  
Stereotactic radiotherapy for intrahepatic cholangiocarcinoma  
Borakati A, Froghi F, Bhogal RH, Mavroidis VK

**1490**  
How the COVID-19 pandemic has affected the colorectal cancer screening in Italy: A minireview  

## ORIGINAL ARTICLE

### Basic Study

**1499**  
Safety and feasibility of irreversible electroporation for the pancreatic head in a porcine model  
Yan L, Liang B, Feng J, Zhang HY, Chang HS, Liu B, Chen YL
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1528</td>
<td>Profiling of gene fusion involving targetable genes in Chinese gastric cancer</td>
<td>Liu ZH, Zhu BW, Shi M, Qu YR, He XJ, Yuan HL, Ma J, Li W, Zhao DD, Liu ZC, Wang BM, Wang CY, Tao HQ, Ma TH</td>
</tr>
<tr>
<td>1540</td>
<td>Adjuvant chemoradiotherapy vs adjuvant chemotherapy in locally advanced Siewert type II/III adenocarcinoma of gastroesophageal junction after D2/R0 resection</td>
<td>Kang WZ, Shi JM, Wang BZ, Xiong JP, Shao XX, Hu HT, Jin J, Tian YT</td>
</tr>
<tr>
<td>1552</td>
<td>Duodenal-type follicular lymphoma more than 10 years after treatment intervention: A retrospective single-center analysis</td>
<td>Saito M, Mori A, Tsukamoto S, Ishio T, Yokoyama E, Izumiyama K, Morioka M, Kondo T, Sugino H</td>
</tr>
<tr>
<td>1562</td>
<td>Evaluation of the diagnostic value of serum-based proteomics for colorectal cancer</td>
<td>Wang HJ, Xie YB, Zhang PJ, Jiang T</td>
</tr>
<tr>
<td>1574</td>
<td>RASSF1A methylation as a biomarker for detection of colorectal cancer and hepatocellular carcinoma</td>
<td>Li J, Li H, Run ZC, Wang ZL, Jiang T, An Y, Li Z</td>
</tr>
</tbody>
</table>

**CASE REPORT**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>

**LETTER TO THE EDITOR**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1594</td>
<td>Exosomes: Promising biomarkers and targets for cancer</td>
<td>Fang Z, Ding YX, Li F</td>
</tr>
<tr>
<td>1597</td>
<td>Colitis and colorectal tumors should be further explored and differentiated</td>
<td>Xu DH, Zhou B, Li ZP, He LP, Wang XJ</td>
</tr>
<tr>
<td>1600</td>
<td>Acute or chronic inflammation role in gastrointestinal oncology</td>
<td>Chen HJ, Liang GY, Chen X, Du Z</td>
</tr>
</tbody>
</table>
ABOUT COVER
Editorial Board Member of World Journal of Gastrointestinal Oncology, Meng Zhou, PhD, Professor, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou 325027, Zhejiang Province, China. zhoumeng@wmu.edu.cn

AIMS AND SCOPE
The primary aim of World Journal of Gastrointestinal Oncology (WJGO, World J Gastrointest Oncol) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

INDEXING/ABSTRACTING
The WJGO is now abstracted and indexed in PubMed, PubMed Central, Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJGO as 3.404; IF without journal self cites: 3.357; 5-year IF: 3.250; Journal Citation Indicator: 0.53; Ranking: 162 among 245 journals in oncology; Quartile category: Q3; Ranking: 59 among 93 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO’s CiteScore for 2021 is 3.6 and Scopus CiteScore rank 2021: Gastroenterology is 72/149; Oncology is 203/360.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Ying-Yi Yuan; Production Department Director: Xiang Li; Editorial Office Director: Jia-Ru Fan.

NAME OF JOURNAL
World Journal of Gastrointestinal Oncology

ISSN
ISSN 1948-5204 (online)

LAUNCH DATE
February 15, 2009

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Monjur Ahmed, Florin Burada

EDITORIAL BOARD MEMBERS

PUBLICATION DATE
August 15, 2022

COPYRIGHT
© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/gerinfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com
Stereotactic radiotherapy for intrahepatic cholangiocarcinoma

Aditya Borakati, Farid Froghi, Ricky H Bhogal, Vasileios K Mavroeidis

Abstract

Intrahepatic cholangiocarcinoma (iCCA) is an aggressive malignancy with an increasing incidence worldwide and poor prognosis, despite several advances and continuous efforts to develop effective treatments. Complete surgical resection is the mainstay of treatment and offers a potentially curative option, but is only possible in less than a third of patients, owing to advanced disease. Chemotherapy is a well-established treatment in the adjuvant and palliative setting, however, confers limited benefit. Conventional radiotherapy is challenging due to local toxicity. With recent advances in stereotactic ablative radiotherapy (SABR), it is now possible to focus ablative beams of radiotherapy precisely aimed at tumours to minimise damage to surrounding viscera. This review details the history, technical background and application of SABR to iCCA, with directions for future research suggested.

Key Words: Cholangiocarcinoma; Intrahepatic; Stereotactic ablative radiotherapy; Stereotactic body radiotherapy; Radiotherapy; Liver cancer; Hepatectomy

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: Intrahepatic cholangiocarcinoma (iCCA) maintains a dismal prognosis despite best available therapy. Complete surgical resection offers a potentially curative option but is feasible in a limited number of cases. This review explores the evolving role of stereotactic ablative radiotherapy (SABR) in the management of iCCA either as an adjuvant to surgical resection, or in cases of recurrent or unresectable disease. Data on the use of SABR as a neoadjuvant/downstaging modality are scarce. Notably, published studies are limited to predominantly retrospective case series. High quality prospective trials evaluating SABR are urgently needed.

INTRODUCTION

Cholangiocarcinoma (CCA) is a rare, aggressive malignancy arising from the biliary epithelium. The overall incidence worldwide is less than 6 cases per 100000, however, this varies significantly from country to country and is significantly more common in East Asia[1,2], with incidences of up to 90 per 100000 reported in Thailand[3].

Prognosis in CCA is dismal with fewer than 10% surviving 5 years after diagnosis. Overall survival (OS) is significantly higher with extrahepatic vs intrahepatic tumours (15% vs < 5%, respectively)[4]. The reasons for the poor survival are predominantly related to the insidious growth of the tumours, with limited clinical symptoms until the disease is disseminated, by which point surgical resection which is the sole curative option is precluded.

CLASSIFICATION OF CCA

CCA can be further subdivided by the site of origin in the biliary tract (Figure 1): Intrahepatic CCAs (iCCA) arise from sites proximal to the second order branches of the right or left hepatic duct up to the canals of Hering, while perihilar CCAs (phCCA), also known as Klatskin tumours, arise between the second order branches of the right and/or left hepatic duct and the cystic duct confluence. Distal CCAs (dCCA) arise between the cystic duct confluence and the ampulla of Vater[5-7]. phCCA and dCCAs are collectively termed extrahepatic CCAs (eCCAs) and account for approximately 80% of all diagnoses of CCAs overall, while the remainder are intrahepatic[6,8]. Morphologically, depending on their pattern of growth and appearance, they are categorised in three different types. The mass-forming type, which is the most frequent, accounts for presentation with a mass, the periductal-infiltrating type is characterised by growth along the wall of the bile duct, and the intraductal-growing type by intraluminal growth[7].

Histologically, CCAs can be broadly subdivided into papillary and mucinous carcinomas[9]. iCCAs show greater variability with further subdivision into small and large bile duct cancer. Small bile ducts are lined by cuboidal epithelium and hepatic stem cells, which may be associated with more aggressive tumours and rarely, mixed hepatocellular CCAs. Large bile duct iCCAs are broadly similar to phCCA and dCCA[10].

PRESENTATION

CCAs are typically asymptomatic in their early stages and manifest clinically only at an advanced stage. Non-specific symptoms such as abdominal pain, night sweats and weight loss may be present in the early stage[11].

Jaundice is a hallmark feature of eCCA as obstruction of large distal bile ducts is needed to obstruct the biliary outflow significantly. Given that iCCAs affect the smaller proximal bile ducts, jaundice is much less frequent, and presentation is more likely to be incidental finding on imaging or after work-up for deranged liver function tests[12].

iCCAs further differ clinically from extrahepatic tumours in that they are more likely to arise on a background of diseased liver parenchyma, much like hepatocellular carcinoma. eCCAs, in contrast, are associated with chronic bile duct inflammation, such as with primary sclerosing cholangitis, choledocholithiasis or, in endemic regions, liver fluke infection[13].
MANAGEMENT OF CCA

Complete surgical resection is the only prospect for cure in CCA, but this is only possible in < 30% of patients due to advanced disease at presentation[14,15]. Surgery ranges from hepatectomy in iCCA, hepatectomy and/or hilar resection in phCCA, or pancreatoduodenectomy in extrahepatic tumours, to liver transplantation in selected cases of CCA[7,16].

Adjuvant gemcitabine-based chemotherapy is now recommended in most international guidelines [17-20], with evidence of increased disease-free survival (DFS)[21]; overall 5-year survival can reach from 44% in dCCA to 20%-40% in phCCA and iCCA[8,16].

In the palliative setting, data is more robust in supporting chemotherapy with several randomised studies confirming the survival benefit of gemcitabine and platinum-based therapies, with a median progression free survival (PFS) of 8.0 mo[22,23]. Second line chemotherapy with FOLFOX regimens has also been shown to be of limited benefit, with an improvement in OS by 1 mo, although PFS was poor at 8.6% at 1 year[24].

Locoregional therapy

Despite institution of surgery or chemotherapy where appropriate, recurrence rates remain high and, consequently, patient survival is still poor in CCA. Locally advanced disease, oligometastases and medical comorbidities may also preclude surgical intervention. Locoregional therapies such as radiofrequency ablation (RFA)[25] and trans-arterial chemo- or radio-embolization (TACE or TARE, the latter also known as selective internal radiotherapy)[26] have been developed for locally advanced and oligometastatic disease. These therapies have also reduced cancer recurrence as adjuvant therapies along with surgery[27].

Radiotherapy is another alternative treatment modality encompassing standard external beam, brachytherapy and stereotactic forms studied. This has several advantages to RFA and TACE/TARE, in particular being non-invasive and, not requiring the target to be near blood vessels as in TARE/TACE.

Although radiotherapy is not included in guidelines for the treatment of CCA, it has been shown to improve survival vs chemotherapy alone for unresectable iCCA in large propensity matched population studies, with reduced hazards of mortality [hazard ratio (HR): 0.80 (95%CI: 0.71-0.91, \( P = 0.001 \)][28,29].

Targeted radiotherapy is challenging due to the radiosensitivity of the liver parenchyma and surrounding gastrointestinal tract, which may result in radiation hepatitis, vomiting, diarrhoea and bowel obstruction resulting from stricturing[30,31]. Stereotactic ablative radiotherapy (SABR) allows for high energy beams of radiation focused on target sites avoiding damage to surrounding tissues.

This review gives an overview of the technology of SABR and its application to intrahepatic CCA, which possesses unique characteristics in comparison to other sites.

SABR

SABR uses multiple beams of radiation focused to a single point in three-dimensional space using a collimation system, as opposed to a single unfocused beam used in conventional radiotherapy. This allows a much larger dose of radiation in a single fraction, whilst avoiding exposure to surrounding tissues[32]. In some cases, the course may be completed in a single fraction. This concept was developed...
initially by Phillips et al[33] at the Karolinska Institute in Sweden in the 1960s to treat intracranial lesions. Their technology would eventually become known as the Gamma Knife (Elekta Instruments Inc., Tucker GA, United States)[33]. It was not until the early 1990s until similar technology was applied outside the brain. Immobilisation of the patient or tracking of visceras is necessary when targeting the thorax and abdomen to avoid off-target visceras and mitigate against motion such as during respiration [34].

Uematsu et al[35] were one of the first to realise the clinical benefits of SABR, in 1998, in patients with locally advanced non-small cell lung cancer who were technically operable but unfit for surgery[35]. Successive studies demonstrated that SABR allowed progression-free survival in 80%–90% of these patients, nearly double that of conventional radiotherapy, with significantly lower toxicity[36].

**SABR in the liver**

Following the above reports Herfarth et al[37] applied this technology to the liver for unresectable, predominantly metastatic tumours of varying origin. They again showed impressive local control (LC) rates of 81% at 18 mo[37]. Larger, contemporary series of SABR mirror Herfarth’s early results in both hepatocellular carcinoma[38] and oligometastatic disease in the liver[39,40]. These series are predominately observational, and no large-scale interventional trial has been published in this population.

Modern approaches to applying SABR in the liver involve immobilising the abdomen using body moulds or vacuum cushions. Movement from respiration is controlled by using controlled breath holding techniques or respiratory gating or tumour tracking with image guidance. Stereotactic frames and/or implanted fiducial markers may be used to provide a reference for anatomical delineation. The above methods are combined with 4D computed tomography scanning to apply SABR, and accuracy to between 2 and 3 mm is achievable[41,42].

Patients suitable for SABR to the liver, typically have fewer than 3 tumours at no larger than 6cm each, situated greater than 5 mm from adjacent visceras so that ablative doses may be more easily achieved, although these criteria will vary depending on institutional experience[41,42].

The side effect profile of SABR in relation to the liver most commonly consists of nausea and fever, which can be seen within a few hours of treatment. These may be prevented with prophylactic antiemetics[43].

Late side effects include radiation induced liver disease (RILD), which may occur between 2 wk and 8 mo after completion of treatment. This includes clinical symptoms of fatigue, tender anicteric hepatomegaly and ascites. Biochemically, there is elevated alkaline phosphatase, whilst transaminases and bilirubin remain normal[44].

Non-classical RILD (typically in patients with underlying liver disease) occurs within 3 mo of radiotherapy and consists of liver enzymes more than five times the upper limit of normal or a decline in liver function as measured by a worsening Child-Pugh score of 2 or more in the absence of classical RILD.

These occur in less than 5% of patients and are associated with cumulative doses (in conventionally fractionated radiotherapy) higher than 30-32 Gy and 28 Gy in patients with underlying liver disease. Other specific toxicities are related to off-target effects on the gastrointestinal tract, with nausea, vomiting and diarrhoea being common. Other effects are common to all radiation therapies, and these include skin necrosis (much less common in the era of volumetric modulated arc therapy) and systemic effects such as fatigue and fever. It should be reiterated that these side effects, when they do occur, are typically milder and less frequent than with equivalent conventional radiotherapy[45].

**APPLICATION OF SABR IN iCCA**

As mentioned above, the standard of care for curative treatment of iCCA is surgical resection followed by adjuvant chemotherapy. For palliative treatment, chemotherapy with gemcitabine and platinum regimes are recommended[17,18]. We therefore focus on five scenarios where SABR may be useful in the treatment algorithm: (1) Primary therapy in patients with technically resectable disease but precluded from resection due to medical comorbidities; (2) Primary therapy in technically unresectable disease; this may be due to diffuse or metastatic disease; (3) Recurrent disease after surgical resection; (4) Following surgical resection to prevent local recurrence (adjuvant therapy); and (5) As a downstaging modality before surgery (neoadjuvant). Relevant studies are summarised in Table 1.

**SABR as primary therapy in medically unresectable iCCA**

Shen et al[46] reported data on SABR in inoperable iCCA. In this series 12/28 (42.8%) were inoperable due to medical co-morbidities or advanced age whilst the remainder were technically inoperable. Data was not stratified by the reason for inoperability, although on multivariable analysis, there was no difference in response based on this. The overall disease control rate with SABR was 89.3%, of which 42.9% had stable disease, 35.7% a partial response and 10.7% a complete response at first follow-up (median 16 mo). Predictors of successful response were median biologically effective doses (BED) of > 100 Gy and having solitary lesions. Median OS was 15.0 mo and median PFS was 11.0 mo. OS and PFS
<table>
<thead>
<tr>
<th>Ref.</th>
<th>Country</th>
<th>Design</th>
<th>Patient characteristics (reason for inoperability)</th>
<th>Total patients</th>
<th>No. iCCA (%)</th>
<th>Median follow-up/months (range)</th>
<th>Outcomes (1 yr)</th>
<th>Major side effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shen et al [46], 2017</td>
<td>China</td>
<td>Retrospective</td>
<td>Unresectable: (1) 7/28 Medical; (2) 10/28 Technical; and (3) 5/28 Advanced age</td>
<td>28</td>
<td>28 (100)</td>
<td>16 (3-42)</td>
<td>Local control</td>
<td>Progression free survival</td>
</tr>
<tr>
<td>Liu et al [47], 2017</td>
<td>Taiwan</td>
<td>Retrospective</td>
<td>Unresectable: (1) Medical 3/15; and (2) Surgical 12/15</td>
<td>15</td>
<td>12 (80)</td>
<td>29.0</td>
<td>89.3</td>
<td>50.0</td>
</tr>
<tr>
<td>Thuehøj et al [48], 2022</td>
<td>Denmark</td>
<td>Retrospective</td>
<td>Unresectable, locally advanced</td>
<td>41</td>
<td>15 (37)</td>
<td>9.5 (0-66.5)</td>
<td>85.4</td>
<td>31.7</td>
</tr>
<tr>
<td>Tao et al [49], 2016</td>
<td>United States</td>
<td>Retrospective</td>
<td>Unresectable, locally advanced</td>
<td>79</td>
<td>79 (100)</td>
<td>24 (4-33)</td>
<td>81.0</td>
<td>91.0</td>
</tr>
<tr>
<td>Tse et al [51], 2006</td>
<td>Canada</td>
<td>Prospective, phase I</td>
<td>Unresectable, locally advanced (includes HCC)</td>
<td>41</td>
<td>10 (24)</td>
<td>17.6 (range 10.8-39.2)</td>
<td>65.0 (all patients)</td>
<td>-</td>
</tr>
<tr>
<td>Mahadevan et al [52], 2015</td>
<td>United States</td>
<td>Retrospective</td>
<td>Unresectable: (1) Medical 3/34; and (2) Surgical 29/34. R1 Resection: 2/34</td>
<td>34</td>
<td>31 (91)</td>
<td>38 (8-71)</td>
<td>88.0</td>
<td>-</td>
</tr>
<tr>
<td>Barney et al [53], 2012</td>
<td>United States</td>
<td>Retrospective</td>
<td>Unresectable: 6/12 lesions. Recurrent: 6/12 lesions</td>
<td>10</td>
<td>6 (60)</td>
<td>14 (2-26)</td>
<td>100%</td>
<td>-</td>
</tr>
<tr>
<td>Brunner et al [54], 2019</td>
<td>Germany and Switzerland</td>
<td>Retrospective, multicentre</td>
<td>Unresectable, unclear reasons</td>
<td>64</td>
<td>41/82 lesions (50%)</td>
<td>35 (7-91) for survivors</td>
<td>89</td>
<td>-</td>
</tr>
<tr>
<td>Weiner et al [55], 2016</td>
<td>United States</td>
<td>Prospective, phase I</td>
<td>Unresectable, locally advanced (includes HCC)</td>
<td>26</td>
<td>14 (54) including 2 biphenotypic ICCA and HCC</td>
<td>8.8 (0.3-33)</td>
<td>91 (all patients)</td>
<td>68</td>
</tr>
<tr>
<td>Kozak et al [56], 2020</td>
<td>United States</td>
<td>Retrospective</td>
<td>Unresectable disease</td>
<td>40</td>
<td>26 (63)</td>
<td>18 (1-100)</td>
<td>70 (all patients)</td>
<td>-</td>
</tr>
<tr>
<td>Sebastian et al [59], 2019</td>
<td>United States</td>
<td>Retrospective, population database study, comparative study between SABR, TARE and CRT</td>
<td>Unresected, locally advanced disease</td>
<td>27-SABR; 52-CRT; TARE-60</td>
<td>141 (100%)</td>
<td>17</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Jung et al [60], 2014</td>
<td>South Korea</td>
<td>Retrospective</td>
<td>Unresectable and recurrent disease after</td>
<td>28-Unresectable; 33 (57)</td>
<td>10 (1-97)</td>
<td>Unresectable-76; Recurrent-91 Overall-26 Unresectable-29; Recurrent-53</td>
<td>2-Cholangitis; 1-Gastric perforation</td>
<td>Not reported</td>
</tr>
</tbody>
</table>
Franzese et al. [61], 2020
Italy Retrospective
49/51 (96%) Recurrent metastatic disease after surgical resection
51 (includes GB adenoCa)
34 (66)-iCCA and eCCA grouped together
14 (3-95)
74.7
32.8
63.2
0

Ibarra et al. [62], 2012
United States Retrospective
Unresectable disease
21-HCC; 11-iCCA
11 (34)
7.8 (1.4-17.9)
55.5
- 
45
0

1Survival and control figures are for intrahepatic cholangiocarcinoma subgroup unless otherwise specified.
iCCA: Intrahepatic cholangiocarcinoma; CTC: Common toxicity criteria; HCC: Hepatocellular carcinoma; SBRT: Stereotactic body radiotherapy; TARE: Trans-arterial radio-embolization; GB adenoCa: Gallbladder adenocarcinoma; eCCA: Extrahepatic cholangiocarcinoma.

were 32.1% and 21.4% at 2 years, respectively[46].

A Taiwanese study included patients with solely medically inoperable tumours (14/15 iCCA). 1- and 2-year OS were 50.3 and 14.4%, while LC was achieved in only 48.5% at 1 year. The reason is likely the lower BED used at 45 Gy and the authors reported significantly higher survival with doses at > 75 Gy, with 1-year OS at 58.3%[47]. A Danish study with predominantly patients with eCCA but who were also medically inoperable showed similar OS and LC rates[48].

The largest study of SABR in iCCA (79 patients) showed 1-year OS of 87% and 3-year OS of 44%. LC rates were 81% and 31%, respectively, for the same time period with a PFS of 88% and 39%. Patients in this study were excluded if treatment was directed with palliative intent, which may explain the higher survival rates, although the authors’ definition of this is unclear. All patients had favourable performance status; 94% scored at 0 or 1, 6% scored 2 and no patients had performance status > 2. 20% of patients had extrahepatic metastatic disease and 58% had nodal disease, implying a poor prognosis pre-treatment[49]. Nevertheless, the survival figures in this study are similar to curative resection, which according to a recent review confers an overall 3-year survival ranging from 32% to 47% and a similar 3-year recurrence free survival which is between 6 to 47%[50]. Survival also correlated with the radiation dose, with a BED greater than 80.5 Gy associated with 3-year OS of 73% vs 38% for patients receiving lower doses.

These results may suggest that SABR could be a suitable alternative to surgical resection in patients unfit for surgery, however comparative studies, in particular, randomized trials are needed to confirm this.

**SABR as primary therapy in technically unresectable iCCA**

Tse et al.[51] provided one of the first reports of SABR in iCCA. Their phase I study included 10 patients with iCCA who were unresectable due to metastatic disease, pre-dominantly confined to the liver or with locoregional lymphadenopathy. The median OS was 15.0 mo with 58% 1-year OS[51].

In Mahadevan et al.’s retrospective study of locally advanced 31 iCCAs (11 further phCCAs or dCCAs), 1-year OS was 58% and 4-year OS was 19%. LC was achieved in 88% at 1 year and 79% at 4 years for the overall cohort. Median PFS was 11 mo after SABR[52].

Barney et al.[53] performed a retrospective study consisting predominantly of patients with either primary or recurrent oligometastatic disease. OS was 73% at 1 year and LC was achieved in 100% of
patients (of whom 25% had a complete response and 42% a partial response). 40% of patients had PFS [53].

A large multicenter German and Swiss study with 64 patients (41 iCCA) showed 1-year OS of 63% and LC at 89%. After multivariable analysis, as above, improved survival and LC were achieved with higher radiation doses, without a significant increase in toxicity[54].

Weiner et al[55] performed a phase II study of SABR in unresectable primary liver lesions of which 14/26 (54%) were iCCA or biphenotypic with HCC. 1-year OS was 51% and PFS was 68% with only 2 of 26 (4%) patients in the study having local progression at the SABR site[55].

Kozak et al[56] performed a retrospective study of SABR in 40 patients with unresectable CCA (23 patients iCCA and the remainder pCCA) assessing the location of failure with respect to the radiation field. Median OS for patients with ICCA was 10 mo, 1-year OS for the entire cohort was 66%, and median follow-up was 18 mo. 12 patients (30%) had in-field local failure, whilst seventeen (42.5%) had out of field hepatic failure. Seven patients (17%) experienced regional failure predominantly in perihilar and para-aortic nodes, whilst 15 patients (37.5%) had distant failure of which the lungs were the most common site of progression (7 patients, 46.7%)[56]. Given the high rates of out of field recurrence, the authors proposed elective nodal irradiation in the perihilar space to prevent regional recurrence, however there are no trials on this.

Bisello et al[57] proposed a series of guidelines on clinical target volumes for biliary tract cancers, including iCCA, to incorporate sites of potential regional progression. They proposed a margin of 9.8mm from the primary tumour boundary to incorporate all microscopic spread[57]. This is at the cost of potential for increased toxicity, in particular around the central biliary tree with suggested dosing limited to for example 42 Gy in 15 fractions or 35 Gy in 5 fractions[58].

One study compared SABR to TARE and conventional chemoradiotherapy in unresectable iCCA using the United States National Cancer Database. Median OS was 20 mo with SABR and significantly greater than TARE and chemoradiotherapy after adjusting for confounders with propensity weighting and multivariable regression [HR: 0.44 (95% CI: 0.21-0.91)][59].

Of note, Jackson et al[28] performed a propensity matched study of patients with inoperable iCCA identified from the United States National Cancer Database comparing patients who received any form of radiotherapy (not specifically SABR). After propensity score matching, they showed that the addition of radiotherapy to the standard chemotherapy regimen significantly reduced the hazards of death [HR: 0.83 (95% CI: 0.71-0.97, P = 0.018)][28].

**SABR for recurrent iCCA**

Jung et al[60] studied patients with unresectable and recurrent disease, of which 57% were iCCAs. 1- and 2-year OS in the recurrent disease group were 53% and 28%, respectively, LC rates were 91% and 81%, respectively, at the same time periods. Overall PFS for all patients were 26% and 23% at 1 and 2 years. Of note, 2 patients developed transient liver failure following SABR in this study[60].

Franzese et al[61] performed a retrospective study of SABR in recurrent biliary tract cancer after surgical resection, of which 18/51 (35%) had iCCA. 1-year OS and PFS were 63.2% and 32.8%, respectively, whilst LC rates were 74.7% at 1 year[61].

Ibarra et al[62] performed a small multi-centre study of 11 patients undergoing SABR for iCCA, with 50% reported as undergoing this following surgical resection and recurrence (the remainder were for unresectable disease, of whom 45% had distant disease). 1-year survival was 45% and LC was estimated to be 55.5% in this study[62].

**SABR as adjuvant treatment for incomplete (R1) resection**

Hammad et al[63] performed a study using the United States National Cancer Database of patients with iCCA who underwent surgical resection. Of the 525 out of 2897 patients who underwent postoperative conventional radiotherapy, 230 (43.8%) had positive resection margins, compared to 704 (24.3%) in the non-radiotherapy group. There was no significant OS benefit [0.99 (95% CI: 0.84–1.16) P = 0.931] for patients who underwent radiotherapy, after propensity score matching and multivariable Cox regression. LC and PFS were not reported[63].

Kim et al[64] published a small case series of 18 patients with incompletely resected iCCA (R1) of whom 7 underwent adjuvant chemoradiotherapy. They found significant increases in OS, LC and PFS with chemoradiotherapy: (LC: 5.6 mo vs not reached, P < 0.001, PFS: 5.6 mo vs 8.3 mo, P = 0.047, OS: 15.0 mo vs 26.6 mo, P = 0.064)[64].

While there are no large studies of SABR specifically, given its advantages over conventional radiotherapy, the above studies could be regarded as showing some promise in its potential use for incomplete resection.

Studies on SABR as standard adjuvant therapy following resection of iCCA are limited, however there is a limited number of studies evaluating conventional radiotherapy following resection.

Jiang et al[65] assessed adjuvant conventional radiotherapy where macroscopic regional lymph nodes were identified following surgical resection on imaging. Out of 100 patients, 24 received radiotherapy, whilst 76 did not, but it was not specified whether the latter patients received any further treatment. Median OS was significantly superior at 68.8% in the radiotherapy group and 12.1% in the non-radiotherapy group (P = 0.01). After multivariable analysis, radiotherapy was independently associated
with survival [HR: 0.482 (95% CI: 0.27-0.86)][65]. A further meta-analysis of studies assessing adjuvant radiotherapy in iCCA did not show a significantly improved patient survival[66].

**SABR and locoregional treatments as a neoadjuvant/downstaging modality**

Studies assessing SABR for downstaging of iCCA (neoadjuvant therapy) have mainly focused on doing this to allow liver transplantation. Wong et al[67] and Sandler et al[68] both reported impressive OS of 80 and 75% at 1 year in the few (4 in each study) patients who underwent liver transplantation following successful SABR. However, 18/22 (82%) in Wong’s study and 27/31 (87%) patients in Sandler’s failed to proceed to transplant, predominantly due to tumour progression.

Conventional chemoradiotherapy has been attempted with promising results in a small case series. Of 7 patients with locally advanced, unresectable iCCA, five (71.4%) became resectable following chemoradiotherapy and one patient remained disease free after resection at 18 mo. 5-year OS was 23.6% [69].

Rayar et al[70] reported their experience of using TARE as a downstaging modality for unresectable iCCA. Of 45 patients who underwent downstaging TARE and chemotherapy, eight (17.7%) ultimately underwent surgical resection with curative intent. With a median follow-up of 15.6 mo, only two patients died perioperatively and only one died from unrelated disease. Of the remainder, two were found to have recurrence at follow-up[70]. Similarly, Edeline and colleagues reported a similar proportion of patients with iCCA downstaged to resectability (9/41, 22%) with TARE, a further two patients remained unresectable, but underwent liver transplantation. For the resected patients, 1-year OS was 88.9% and DFS was 66.8%. For both of the patients undergoing liver transplantation, solitary lung recurrence occurred at 15 and 16 mo and both were alive at 19 and 18 mo of follow-up[71].

**Side effects and quality of life**

Side effects were shown to be transient and mild in the majority of patients in these studies of SABR. Those studies which reported liver function tests, showed mildly deranged values of all parameters (alkaline phosphatase, alanine transaminase, aspartate transaminase and bilirubin) in most patients following SABR. Very few studies reported greater than 40% of patients having grade II symptoms. Of these, the majority are gastrointestinal side effects with nausea and diarrhoea being common.

Although bowel obstruction and perforation may be complications of radiotherapy, only one case of gastric perforation requiring surgery was found in the studies included in the review. Radiation hepatitis was rare and liver failure was reported in only 2 patients in all the studies included in this review.

One study evaluated the quality of life in patients undergoing SABR in the liver and showed a reduction in quality of life in terms of appetite and fatigue within 1 mo of treatment but returning to baseline after 3 mo. These features demonstrate overall that SABR is tolerated well, relative to other therapies[72].

**CONCLUSION**

**Current and future directions for research**

A search of the clinicaltrials.gov registry (search terms “cholangiocarcinoma” and “stereotactic”) showed 2 actively recruiting trials evaluating stereotactic radiotherapy. Of these two, the CORRECT trial (NCT03898895) is a multicentre randomized trial evaluating a programmed cell death ligand 1 checkpoint inhibitor (Camrelizumab) with either SABR or conventional radiotherapy vs standard gemcitabine chemotherapy in unresectable iCCA[73]. The second is a phase II trial of nivolumab with SABR in unresectable iCCA and dCCA[74].

Of the remainder, 4 studies assess all types of liver tumours, 2 assess pCCA only, and the rest assess a mix of extrahepatic and intrahepatic tumours. These are all phase I and II trials.

In addition, the ABC-07 trial is actively recruiting and is a multicentre randomized controlled trial comparing chemotherapy vs chemotherapy and SABR in unresectable CCA (of all types) and gallbladder carcinoma[75].

Furthermore, the ACCTICA-1 trial is primarily assessing the superiority of gemcitabine and cisplatin vs capcitabine in patients with resected CCA and gallbladder adenocarcinoma. However, within this trial there is a sub-study evaluating conventional radiotherapy in patients with R1 resections[76,77].

Thus far, there have been no published randomized trials of SABR in any subgroup of iCCA, and the majority are retrospective single institution studies. Few studies have compared SABR to a control group or other locoregional therapies. There is limited literature on SABR as a downstaging modality prior to standard surgical resection of iCCA, despite evidence of excellent LC in patients who are inoperable.

High quality prospective clinical trials of SABR are urgently needed in homogeneous groups of iCCA, to explore its role as an adjuvant and neoadjuvant therapy either prior to resection or liver transplantation, and as a treatment modality in recurrent and unresectable disease.
Borakati A et al. Stereotactic radiotherapy-iCCA

FOOTNOTES

Author contributions: Mavroeidis VK conceptualised and designed the study; Borakati A did the literature search; Borakati A and Froghi F did the analysis, interpretation of data and drafted the original manuscript; Bhogal RH and Mavroeidis VK supervised and made critical revisions; all authors prepared the final draft and approved the final version.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: United Kingdom

ORCID number: Aditya Borakati 0000-0003-0457-4944; Farid Froghi 0000-0002-2895-117X; Ricky H Bhogal 0000-0002-5053-7979; Vasileios K Mavroeidis 0000-0002-8188-3575.

Corresponding Author’s Membership in Professional Societies: General Medical Council (UK), No. 7451513; Royal College of Surgeons of England, No. 9092145; International College of Surgeons, No. M21313; Faculty of Surgical Trainers of Edinburgh, Royal College of Surgeons of Edinburgh, No. 188646; American College of Surgeons, No. 03340060.

S-Editor: Fan JR
L-Editor: A
P-Editor: Fan JR

REFERENCES


Borakati A et al. Stereotactic radiotherapy-iCCA